The “King of GLP-1s” Debate — My Honest Take I get this question constantly: “Is Retatrutide the new King of GLP-1s?” My answer? It’s not that simple — and it’s definitely not for everyone. Retatrutide adds a third hormone, glucagon, which can boost metabolism and energy expenditure. Tirzepatide (Mounjaro/Zepbound) works primarily on GLP-1 and GIP, which are powerful for appetite regulation and glucose control — but the added glucagon in Retatrutide can change the experience. Here’s what that can mean: - 🔥 Metabolism boost: Retatrutide may increase calorie burn. - 🍽️ Slightly less appetite suppression: Because you’re burning more, your body may feel less “satisfied” than with Tirzepatide. - ⏳ Slower onset: Many users find that appetite suppression takes longer to kick in. - ⚖️ Weight loss differences: Clinical data and anecdotal reports suggest results may appear at higher doses of Retatrutide compared to lower doses of Tirzepatide. My Personal Experience I’ve been microdosing Tirzepatide (2 mg/week) since mid-May and lost about 30 lbs. Recently, I decided to test Retatrutide (0.5 mg/week) as a way to maintain weight loss while focusing on building lean muscle — since my appetite was so low I wasn’t eating enough to fuel my workouts. My first dose of Retatrutide hit me hard: Within hours, I experienced hot sweats and a racing heart that triggered anxiety. I took two weeks off and tried again — but the same thing happened. At a family dinner, I suddenly became dizzy, flushed, and had to step outside to catch my breath. (At 41, I wondered if it was perimenopause — but I’m pretty sure it wasn’t.) So if you’re considering switching, especially if you have any heart concerns or anxiety, start low and slow — and always with medical supervision. Key Takeaway Every GLP-1 therapy works a little differently for every body. Tirzepatide has been steady, predictable, and effective for me; Retatrutide may have incredible potential for others — but it’s more complex and still being studied.